Prevention of ER-negative breast cancer: Where do we stand?

Massimiliano Cazzaniga, Bernardo Bonanni

Research output: Contribution to journalArticlepeer-review


Oestrogen receptor-negative and triple-negative breast cancers are types of aggressive tumours that account for approximately 30 and 15% of total breast cancers, respectively. Selective oestrogen receptor modulators and aromatase inhibitors are unable to treat and prevent these subtypes of mammary tumours. Thus, it is worth identifying new pathways, biomarkers, and agents that are effective in the treatment and prevention of these subtypes. Several classes of drugs have been studied, and many are still currently under investigation. We have attempted to conduct a state-of-the-art study on this important issue.

Original languageEnglish
Pages (from-to)171-181
Number of pages11
JournalEuropean Journal of Cancer Prevention
Issue number2
Publication statusPublished - Mar 2012


  • Breast cancer
  • Oestrogen receptor negative
  • Prevention

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Epidemiology
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Prevention of ER-negative breast cancer: Where do we stand?'. Together they form a unique fingerprint.

Cite this